NYSE$COR
Cencora Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Cencora reported revenue increase driven by U.S. Healthcare Solutions segment, with GAAP diluted EPS of $2.50 and adjusted diluted EPS of $3.73, and raised adjusted diluted EPS guidance for fiscal year 2025.
Cencora reported a strong start to fiscal year 2025, with revenue increasing by 12.8% year-over-year to $81.5 billion. GAAP diluted EPS was $2.50, while adjusted diluted EPS increased by 13.7% to $3.73. The company has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.25 to $15.55.
- Revenue increased by 12.8% year-over-year to $81.5 billion.
- GAAP diluted EPS was $2.50, a decrease compared to the prior year's $2.98.
- Adjusted diluted EPS increased by 13.7% to $3.73, from $3.28 in the prior year.
- Adjusted diluted EPS guidance for fiscal year 2025 has been raised to $15.25 to $15.55.
Headline financials
Revenue & EPS history
Cencora · Revenue · Quarterly
$81.5B
Forward guidance
Cencora updated its fiscal year 2025 financial guidance for revenue, operating income, net interest expense, and adjusted diluted EPS following the closing of the RCA acquisition and continued momentum in the U.S. Healthcare Solutions reportable segment.
Tailwinds
- Revenue growth to be in the range of 8 to 10 percent.
- U.S. Healthcare Solutions revenue growth to be in the range of 9 to 11 percent.
- Adjusted diluted EPS to be in the range of $15.25 to $15.55.
- Adjusted consolidated operating income growth to be in the range of 11.5 to 13.5 percent.
- U.S. Healthcare Solutions segment operating income growth to be in the range of 14.5 to 16.5 percent.
Headwinds
- International Healthcare Solutions revenue growth to be in the range of 4 to 5 percent.
- International Healthcare Solutions segment as reported operating income growth to be flat.
- Net interest expense to be in the range of $290 million to $310 million.
- Weighted average diluted shares outstanding is expected to be under 196 million.
- The Company does not provide forward-looking guidance on a GAAP basis as to certain financial information, where the probable significance of the information cannot be determined, is not available or cannot be reasonably estimated.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.1%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
35 / 73 earnings
Positive
+7.8%
Q2 2019
Best reaction
-18.4%
Q2 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -18.4% | -16.6% | -10.1% | |
| Q1 2026 | -5.9% | +0.4% | -0.9% | |
| Q4 2025 | +2.9% | +5.8% | -1.4% | |
| Q3 2025 | -2.9% | -0.6% | +0.1% | |
| Q2 2025 | +4.6% | -4.3% | -0.6% | |
| Q1 2025 | +0.7% | -2.1% | +1.2% | |
| Q4 2024 | +5.9% | +6.5% | +4.0% | |
| Q3 2024 | +5.8% | +4.4% | +3.7% | |
| Q2 2024 | -6.0% | -6.3% | -5.2% | |
| Q1 2024 | +7.4% | +6.2% | +7.5% | |
| Q4 2023 | +4.2% | +4.7% | +9.0% | |
| Q3 2023 | +1.2% | -1.3% | -7.5% | |
| Q2 2023 | +0.1% | +0.7% | +3.5% | |
| Q1 2023 | -6.2% | -8.6% | -7.6% | |
| Q4 2022 | +4.4% | +3.1% | +12.4% | |
| Q3 2022 | -2.5% | -1.5% | +3.4% | |
| Q2 2022 | +2.9% | +4.4% | -2.5% | |
| Q1 2022 | +0.2% | +1.3% | +7.0% | |
| Q4 2021 | -0.6% | -2.8% | -9.0% | |
| Q3 2021 | -1.5% | -2.8% | +1.2% | |
| Q2 2021 | -6.5% | -2.1% | -7.1% | |
| Q1 2021 | +3.9% | +1.8% | -0.7% | |
| Q4 2020 | -1.0% | +4.8% | -1.9% | |
| Q3 2020 | -3.0% | -1.6% | -7.7% | |
| Q2 2020 | +3.0% | +3.6% | +15.8% | |
| Q1 2020 | -4.8% | -2.0% | -6.2% | |
| Q4 2019 | +1.6% | +1.0% | +4.2% | |
| Q3 2019 | +3.8% | -3.5% | -5.6% | |
| Q2 2019 | +7.8% | +5.5% | +6.1% | |
| Q1 2019 | +6.7% | +9.2% | +5.7% | |
| Q4 2018 | -2.3% | +0.3% | -2.9% | |
| Q3 2018 | +1.9% | +5.0% | +13.2% | |
| Q2 2018 | -4.3% | -5.1% | -6.6% | |
| Q1 2018 | +2.5% | -2.9% | +4.7% | |
| Q4 2017 | -2.4% | -2.2% | +10.9% | |
| Q3 2017 | -11.4% | -12.0% | -12.1% | |
| Q2 2017 | +3.9% | +5.9% | +13.2% | |
| Q1 2017 | +6.0% | +6.8% | +9.9% | |
| Q4 2016 | +3.6% | +3.1% | +12.9% | |
| Q3 2016 | +5.1% | +4.5% | +1.9% | |
| Q2 2016 | -9.2% | — | — | |
| Q1 2016 | -3.7% | — | — | |
| Q4 2015 | -1.0% | — | — | |
| Q3 2015 | -5.4% | — | — | |
| Q2 2015 | +1.9% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | +7.1% | — | — | |
| Q3 2014 | +3.7% | — | — | |
| Q2 2014 | -3.1% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.8% | — | — | |
| Q3 2013 | -0.0% | — | — | |
| Q2 2013 | -4.6% | — | — | |
| Q1 2013 | -5.1% | — | — | |
| Q4 2012 | -0.6% | — | — | |
| Q3 2012 | +2.7% | — | — | |
| Q2 2012 | -1.2% | — | — | |
| Q1 2012 | +2.4% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q3 2011 | -0.5% | — | — | |
| Q2 2011 | +2.9% | — | — | |
| Q1 2011 | +0.5% | — | — | |
| Q4 2010 | -0.5% | — | — | |
| Q3 2010 | -0.7% | — | — | |
| Q2 2010 | +1.0% | — | — | |
| Q1 2009 | -1.7% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | -0.6% | — | — | |
| Q2 2009 | -0.6% | — | — | |
| Q4 2007 | -0.6% | — | — | |
| Q3 2008 | -0.5% | — | — | |
| Q3 2009 | -0.5% | — | — | |
| Q4 2008 | -0.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro